,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,debtToEquity,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,863 Mitten Road,Suite 102,Burlingame,CA,94010,United States,650 900 4520,https://www.corvuspharma.com,Biotechnology,Healthcare,"Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.",29,"{'maxAge': 1, 'name': 'Dr. Richard A. Miller M.D.', 'age': 71, 'title': 'Co-Founder, Pres, CEO & Chairman', 'yearBorn': 1951, 'fiscalYear': 2022, 'totalPay': 306000, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.57,1.59,1.55,1.6,1.57,1.59,1.55,1.6,0.0,0.973374,-3.0980394,132837,132837,419458,559010,559010,1.56,1.58,900,1000,77366128,0.607,4.19,2.2252,1.5798,0.0,0.0,USD,41858404,0.0,36809597,48965900,1371300,1160194,1690761600,1693440000,0.027999999,0.040939998,0.45547,5.44,0.0372,1.012,1.5612649,1672444800,1703980800,1688083200,-39023000,-0.77,-0.51,-1.409,NGM,EQUITY,CRVS,CRVS,"Corvus Pharmaceuticals, Inc.","Corvus Pharmaceuticals, Inc.",1458739800,America/New_York,EDT,-14400000,1.58,12.0,3.5,7.1,8.0,1.6,buy,5,37017000,0.756,-29703000,1999000,4.715,4.824,4.04,-0.2489,-0.60096,-17644000,-27810000,0.0,0.0,0.0,USD,
1,863 Mitten Road,Suite 102,Burlingame,CA,94010,United States,650 900 4520,https://www.corvuspharma.com,Biotechnology,Healthcare,"Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.",29,"{'maxAge': 1, 'name': 'Dr. Peter A. Thompson FACP, M.D.', 'age': 62, 'title': 'Co-Founder & Independent Director', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 47000, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.57,1.59,1.55,1.6,1.57,1.59,1.55,1.6,0.0,0.973374,-3.0980394,132837,132837,419458,559010,559010,1.56,1.58,900,1000,77366128,0.607,4.19,2.2252,1.5798,0.0,0.0,USD,41858404,0.0,36809597,48965900,1371300,1160194,1690761600,1693440000,0.027999999,0.040939998,0.45547,5.44,0.0372,1.012,1.5612649,1672444800,1703980800,1688083200,-39023000,-0.77,-0.51,-1.409,NGM,EQUITY,CRVS,CRVS,"Corvus Pharmaceuticals, Inc.","Corvus Pharmaceuticals, Inc.",1458739800,America/New_York,EDT,-14400000,1.58,12.0,3.5,7.1,8.0,1.6,buy,5,37017000,0.756,-29703000,1999000,4.715,4.824,4.04,-0.2489,-0.60096,-17644000,-27810000,0.0,0.0,0.0,USD,
2,863 Mitten Road,Suite 102,Burlingame,CA,94010,United States,650 900 4520,https://www.corvuspharma.com,Biotechnology,Healthcare,"Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.",29,"{'maxAge': 1, 'name': 'Mr. Leiv  Lea', 'age': 68, 'title': 'Chief Financial Officer', 'yearBorn': 1954, 'fiscalYear': 2022, 'totalPay': 388731, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.57,1.59,1.55,1.6,1.57,1.59,1.55,1.6,0.0,0.973374,-3.0980394,132837,132837,419458,559010,559010,1.56,1.58,900,1000,77366128,0.607,4.19,2.2252,1.5798,0.0,0.0,USD,41858404,0.0,36809597,48965900,1371300,1160194,1690761600,1693440000,0.027999999,0.040939998,0.45547,5.44,0.0372,1.012,1.5612649,1672444800,1703980800,1688083200,-39023000,-0.77,-0.51,-1.409,NGM,EQUITY,CRVS,CRVS,"Corvus Pharmaceuticals, Inc.","Corvus Pharmaceuticals, Inc.",1458739800,America/New_York,EDT,-14400000,1.58,12.0,3.5,7.1,8.0,1.6,buy,5,37017000,0.756,-29703000,1999000,4.715,4.824,4.04,-0.2489,-0.60096,-17644000,-27810000,0.0,0.0,0.0,USD,
3,863 Mitten Road,Suite 102,Burlingame,CA,94010,United States,650 900 4520,https://www.corvuspharma.com,Biotechnology,Healthcare,"Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.",29,"{'maxAge': 1, 'name': 'Dr. William Benton Jones Ph.D.', 'age': 56, 'title': 'Sr. VP of Pharmaceutical Devel.', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 346419, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.57,1.59,1.55,1.6,1.57,1.59,1.55,1.6,0.0,0.973374,-3.0980394,132837,132837,419458,559010,559010,1.56,1.58,900,1000,77366128,0.607,4.19,2.2252,1.5798,0.0,0.0,USD,41858404,0.0,36809597,48965900,1371300,1160194,1690761600,1693440000,0.027999999,0.040939998,0.45547,5.44,0.0372,1.012,1.5612649,1672444800,1703980800,1688083200,-39023000,-0.77,-0.51,-1.409,NGM,EQUITY,CRVS,CRVS,"Corvus Pharmaceuticals, Inc.","Corvus Pharmaceuticals, Inc.",1458739800,America/New_York,EDT,-14400000,1.58,12.0,3.5,7.1,8.0,1.6,buy,5,37017000,0.756,-29703000,1999000,4.715,4.824,4.04,-0.2489,-0.60096,-17644000,-27810000,0.0,0.0,0.0,USD,
4,863 Mitten Road,Suite 102,Burlingame,CA,94010,United States,650 900 4520,https://www.corvuspharma.com,Biotechnology,Healthcare,"Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.",29,"{'maxAge': 1, 'name': 'Dr. James T. Rosenbaum M.D.', 'title': 'Sr. VP of Research', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,1.57,1.59,1.55,1.6,1.57,1.59,1.55,1.6,0.0,0.973374,-3.0980394,132837,132837,419458,559010,559010,1.56,1.58,900,1000,77366128,0.607,4.19,2.2252,1.5798,0.0,0.0,USD,41858404,0.0,36809597,48965900,1371300,1160194,1690761600,1693440000,0.027999999,0.040939998,0.45547,5.44,0.0372,1.012,1.5612649,1672444800,1703980800,1688083200,-39023000,-0.77,-0.51,-1.409,NGM,EQUITY,CRVS,CRVS,"Corvus Pharmaceuticals, Inc.","Corvus Pharmaceuticals, Inc.",1458739800,America/New_York,EDT,-14400000,1.58,12.0,3.5,7.1,8.0,1.6,buy,5,37017000,0.756,-29703000,1999000,4.715,4.824,4.04,-0.2489,-0.60096,-17644000,-27810000,0.0,0.0,0.0,USD,
